Clinical trial · Observational
Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy
Projecting Survival for Patients Treated With First-Line Ipilimumab-Nivolumab Combination Therapy Using a Prognostic Model and Cost Per Responder Model of Ipilimumab-Nivolumab Combination Therapy
NCT03438279CI-TRIAL-00031710completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will review published trial literature and documents for Overall Survival (OS) to evaluate the association between the hazard of death and each baseline variable.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Non-Interventional | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- First-Line Ipilimumab
- description
- patients who received ipilimumab as their first-line treatment
- interventionNames
- Other: Non-Interventional
Primary outcomes (1)
- measure
- Prognostic Model of Overall Survival (OS)
- timeFrame
- 10 years
- description
- The OS prognostic model uses Individual patient data from a pooled analysis of 12 ipilimumab studies.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of melanoma Exclusion Criteria: * Age less than 18 years old
References
Publications (0)
Data not yet available
No reference posted for this study.